News & Events:MRK

Someone with a lot of money to spend has taken a bearish stance on Merck & Co. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

IO Biotech dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA®  in patients with previously untreated, unresectable or metastatic melanoma. The Phase 3 IOB-013 / KN-D18 clinical trial will evaluate IO102-IO103 in combination with Merck's anti-PD-1therapy for patients with metastatic melanoma.

Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc's (PFE) oral antiviral treatment Paxlovid seeing a 315% jump over the past four weeks, U.S. health officials said on Tuesday.

Use of Pfizer Inc's COVID-19 oral antiviral treatment Paxlovid has jumped 315% over the past four weeks, the U.S. Department of Health and Human Services said on Tuesday. Nearly 115,000 courses of the pills were dispensed during the first week of May, a senior health official said.

On CNBC's "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management chose Invesco S&P 500 Low Volatility ETF, saying that "we have to fight through some more bumps for the next couple of months." Jim Lebenthal of Cerity Partners said Kinder Morgan Inc is a "laggard in the energy space." Lebenthal added that he believes the stock is "starting to break out right here."

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Delta Air Lines, Inc. 12:44 P.M. - The stock gained 0.24% after Steve Weiss mentioned he bought shares of Delta while acknowledging the stock is down 20% from its highs.

Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer

Adage Capital Partners GP LLC: * ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN DUPONT BY 94.9% TO 1.1 MILLION SHARES - SEC FILING. * ADAGE CAPITAL PARTNERS GP LLC CUTS SHARE STAKE IN MERCK BY 31.7% TO 1.2 MILLION SHARES. * ADAGE CAPITAL PARTNERS GP LLC UPS SHARE STAKE IN PG&E CORP BY 38.9% TO 1.3 MILLION SHARES.

Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Cocrystal Pharma reported 2022 1st quarter results on May 11, 2022. General & Administrative expenses were $1.33 million which was below our expectations due to lower-than-expected professional fees. Net loss for the quarter was $4.2 million, or per diluted share, which was in line with our expectations.

Several generic drugmakers that will produce versions of Pfizer's COVID-19 antiviral treatment Paxlovid have agreed to sell the medicine in low- and middle-income countries for $25 a course or less, the Clinton Health Access Initiative said on Thursday.

On CNBC's "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said Charles Schwab Corporation is trading at 14 times next year's earnings. Degas Wright of Decatur Capital Management cited Hologic, Inc. saying he likes the company for its "strong growth and diagnostics and imaging products." Check out other medical and tech stocks making big moves in the premarket.

A look at the day ahead from Danilo Masoni. The return of U.S. inflation to more bearable levels is not going to happen overnight so those who were hoping for a clear signal that price pressures had peaked got disappointed.

A look at the day ahead from Danilo Masoni. April's hot consumer price data did leave bets of aggressive Fed tightening broadly intact and with them the spectre that a hard landing for the world's top economy may become unavoidable.

The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say.

The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say.

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned.

- Pfizer Inc's (PFE) $11.6 billion deal for migraine specialist Biohaven Pharmaceutical (BHVN) has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

Pfizer Inc's (PFE) $11.6 billion deal for migraine specialist Biohaven Pharmaceutical (BHVN) has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

* Drug candidate tiragolumab previously flunked trial in March. * Anti-TIGIT class of drugs has attracted several rivals. * Roche says trial will continue after disappointing interim data. By Ludwig Burger. May 11 - Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when the drug, tiragolumab, failed to slow progression of lung cancer in a second trial.